HTML Test Page
Test here
- YoY Gross Revenue: Gross revenue grew 7.7% to reach $214,398 in 2026, up from $197,697 in 2025.
- Insider Shares: No insider share liquidation recorded over the previous three years
- No Convertible Debt: None issued
- Capital Resources: Completely self-financed. As of June 30, 2026, the Company’s conservative, equity-financed structure yields an 8.8% Debt-to-Equity ratio, minimizing solvency risk.
- Distribution Scale: Through Tier-1 carrier alliances and InsureTech partnerships, Novus has immediate access to over 15,000 agents and millions of prospective policyholders.
- Dual Platform: Prescription Drug Platform is separate from the cannabis ordering platform
